GE Healthcare has identified radiopharmaceuticals as a growth driver for the company and Japan as a key market.

NMP's product range includes GE HealthCare radiopharmaceuticals, which are essential for imaging in cardiology, oncology, and ...

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to reveal her latest portfolio moves. Trade Tracker: ...

GE HealthCare(GEHC.US)已同意从Sumitomo Chemical手中收购Nihon ...

智通财经获悉，GE HealthCare(GEHC.US)已同意从Sumitomo Chemical手中收购Nihon ...

GE HealthCare全球介入业务总经理Arnaud Marie解释说，自然的身体运动和扫描中造影剂的分布历来会产生伪影，这给CBCT图像的清晰解读带来挑战。CleaRecon DL是GE HealthCare针对这一障碍的回应，旨在使医生和患者都能受益于先进的成像技术。

GE HealthCare (GEHC) has agreed to acquire the remaining 50% stake in Nihon Medi-Physics ((NMP)) from Sumitomo Chemical. Read ...

GE HealthCare (Nasdaq:GEHC) announced today that it submitted its CleaRecon DL technology for FDA 510(k) clearance.

Physics, maker of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control of ...

The Chicago-based medical device and technology giant plans to purchase the remaining 50% stake in Nihon Medi-Physics.

GE HealthCare has unveiled a new mammography system with artificial-intelligence-powered features that it says are aimed at ...

在其他近期新闻中，GE HealthCare在运营和财务表现方面取得了重大进展。公司报告最近一个季度有机收入增长1%，总收入达到$49亿。调整后的EBIT利润率提高到16.3%，调整后每股收益上升到$1.14，同比增长15%。公司的订单积压现已达到$196亿，主要由服务合同和多年企业交易贡献。